BPC-157 — Body Protection Compound 157 — is a synthetic pentadecapeptide derived from a protein found in human gastric juice. It is one of the most extensively studied repair-focused peptides in the preclinical literature, with over 20 years of animal research investigating its effects on tendons, ligaments, the gastrointestinal tract, and the central nervous system. As of 2026, BPC-157 carries an Evidence Tier C rating — meaning the preclinical data is compelling and wide-ranging, but robust human randomised controlled trial (RCT) data remains limited. This guide covers everything a serious researcher needs to understand: mechanism of action, evidence status, dosage protocols, the Wolverine Stack, reconstitution, and the biomarkers worth monitoring. All information is for research and educational purposes only.
What Is BPC-157?
BPC-157 (Body Protection Compound 157) is a synthetic pentadecapeptide — a chain of 15 amino acids — derived from a naturally occurring protein sequence found in human gastric juice. Its full sequence is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. Unlike most peptides, BPC-157 is remarkably stable in gastric acid, which is why it retains activity when administered orally — a unique property among research peptides. The synthetic version used in research is chemically identical to the naturally occurring sequence but produced under controlled laboratory conditions without the gastric protein carrier. It is stable at room temperature in its lyophilised form and remains biologically active across a range of pH environments, making it one of the most versatile peptides currently studied.
The name "Body Protection Compound" comes from the broad cytoprotective effects observed in early gastric research. BPC-157 was first isolated and characterised by Dr. Predrag Sikiric and his team at the University of Zagreb, beginning in the 1990s. Their work established the foundation for what is now one of the most cited preclinical peptide research bodies in the literature, spanning well over 80 published studies.
Key fact: BPC-157 is stable in human gastric acid — unlike virtually every other research peptide. This makes oral administration a viable route for gut-targeted research, distinguishing it from peptides that require subcutaneous or IV administration.
Evidence Tier & Research Status
Tier C — Promising Preclinical, Limited Human RCT DataBPC-157 is classified as Evidence Tier C on the Bioactive Compounds research framework. Tier C compounds have substantial, reproducible animal study data showing clear biological effects, but lack the body of human randomised controlled trial (RCT) evidence required to move to Tier B or Tier A. What the animal studies show is significant: multiple independent research groups have replicated beneficial effects across tendon healing, intestinal barrier integrity, systemic anti-inflammatory activity, and central nervous system protection. What remains uncertain is how these findings translate to human subjects, what the optimal human dose is, and what the long-term safety profile looks like over multi-year use. Honest appraisal of the evidence requires acknowledging both the depth of preclinical data and the gap in human clinical evidence.
The preclinical research profile for BPC-157 covers a remarkable breadth of tissue types and injury models. Studies have demonstrated accelerated tendon-to-bone healing in rodent models, reduction in inflammatory markers in gut injury models, neuroprotective effects in brain trauma models, and systemic effects on blood pressure and nitric oxide pathways. The University of Zagreb group has published extensively in peer-reviewed journals including the Journal of Physiology (Paris), Inflammation Research, and Biomedicines.
| Research Domain | Study Quality | Replication | Human Data |
|---|---|---|---|
| Tendon / Ligament Healing | Multiple rodent models | High | None (RCT) |
| Gastrointestinal Healing | Multiple rodent + pig models | Very High | Limited case reports |
| Muscle Repair | Rodent crush injury | Moderate | None |
| CNS / Neuroprotection | Rodent brain injury models | Moderate | None |
| Systemic Anti-inflammation | Multiple cytokine studies | High | None (RCT) |
How BPC-157 Works — Mechanism of Action
BPC-157 operates through several interconnected molecular pathways. The best characterised include: (1) Growth hormone receptor upregulation — BPC-157 has been shown to increase GHR expression on target tissues, potentiating local growth factor signalling without directly stimulating systemic GH release. (2) VEGF pathway activation — it promotes vascular endothelial growth factor expression, driving angiogenesis (new blood vessel formation) into damaged tissue, which is mechanistically critical for tendon and ligament healing. (3) Nitric oxide modulation — BPC-157 influences both constitutive and inducible NO synthase pathways, contributing to its anti-inflammatory and gastroprotective effects. (4) Cytoprotection of gut epithelium — it upregulates protective pathways in gastrointestinal cells, maintaining mucosal barrier integrity under chemical and ischaemic stress. (5) Fibroblast proliferation — tendon-to-bone healing specifically involves enhanced fibroblast activity at the enthesis interface, the critical zone where soft tissue meets bone.
The multi-pathway nature of BPC-157's mechanism is one reason it is studied across such diverse tissue types. Unlike single-pathway compounds, BPC-157 appears to act at a systems level — modulating several repair and protective cascades simultaneously. This is not unique to BPC-157 among gastric-derived peptides, but the breadth of documented downstream effects is notable. Researchers should note that these mechanisms have primarily been characterised in in vitro and rodent models; the degree to which they operate identically in humans is an open research question.
BPC-157 Dosage — Research Protocols
The most commonly used dosage in published animal research, when extrapolated to human equivalent using body surface area conversion (BSA), falls in the range of 250–500 mcg per dose. Research protocols typically employ once-daily administration, either subcutaneously (systemic distribution) or via local injection near the target tissue (for injury-specific applications). Cycle lengths of 8–12 weeks are standard, with off-cycle periods of 4–8 weeks before repeating. Morning administration is most common in systemic protocols; pre-bedtime dosing is used in some gut-focused protocols where overnight mucosal recovery is the research target. There is no strong evidence supporting fractional twice-daily dosing over single daily administration for most applications. Higher doses (above 500 mcg/day) are not supported by proportionally greater effects in the available research, and some animal studies suggest a bell-curve dose response at very high concentrations.
Dosage Reference Table
| Protocol Type | Dose | Frequency | Route | Cycle |
|---|---|---|---|---|
| Standard Systemic | 250–500 mcg | Once daily | SubQ | 8–12 weeks on / 4–8 weeks off |
| Local (Injury-focused) | 200–250 mcg | Once daily | SubQ near site | 6–8 weeks |
| Gut-targeted | 250 mcg | Once daily | Oral | 4–8 weeks |
| Wolverine Stack | 250 mcg BPC + 750 mcg TB-500 | Once daily | SubQ (shared pen) | 8–12 weeks on / 4 weeks off |
Reconstitution Guide
BPC-157 is supplied as a lyophilised white powder in sealed vials, typically in 2 mg, 5 mg, or 10 mg quantities. Reconstitution uses Bacteriostatic Water (BAC water) — sterile water with 0.9% benzyl alcohol as a preservative, which extends the shelf life of the solution once prepared. The standard reconstitution calculation: add 2 ml of BAC water to a 5 mg vial to produce a concentration of 2,500 mcg/ml (1 ml = 2,500 mcg; 0.1 ml = 250 mcg). For a 2 mg vial with 2 ml BAC water: 1,000 mcg/ml (0.25 ml = 250 mcg; 0.5 ml = 500 mcg). Reconstituted solution must be stored at 2–8°C and used within 28 days. Always swirl gently to mix — never shake. Shaking introduces air bubbles and can degrade peptide structure through mechanical shear forces.
Reconstitution Calculation Examples
| Vial Size | BAC Water Added | Concentration | 250 mcg dose draw | 500 mcg dose draw |
|---|---|---|---|---|
| 2 mg (2,000 mcg) | 2 ml | 1,000 mcg/ml | 0.25 ml (25 IU) | 0.50 ml (50 IU) |
| 5 mg (5,000 mcg) | 2 ml | 2,500 mcg/ml | 0.10 ml (10 IU) | 0.20 ml (20 IU) |
| 5 mg (5,000 mcg) | 5 ml | 1,000 mcg/ml | 0.25 ml (25 IU) | 0.50 ml (50 IU) |
| 10 mg (10,000 mcg) | 5 ml | 2,000 mcg/ml | 0.125 ml (12.5 IU) | 0.25 ml (25 IU) |
Step-by-step reconstitution procedure:
- Allow the vial to reach room temperature before opening (reduces vacuum pressure differential).
- Wipe the rubber septum of both the peptide vial and BAC water vial with an alcohol swab; allow to dry.
- Draw the calculated volume of BAC water into a sterile insulin syringe.
- Insert the needle at an angle against the inside wall of the peptide vial — direct the stream of BAC water down the glass wall, not onto the peptide powder directly.
- Remove needle. Gently swirl the vial in circular motions until the powder is fully dissolved. Do not shake.
- The solution should be clear and colourless. Any cloudiness or particulates indicate contamination or degradation — discard.
- Label the vial with the date of reconstitution. Use within 28 days. Store at 2–8°C.
The Wolverine Stack — BPC-157 + TB-500
The Wolverine Stack pairs BPC-157 with TB-500 (Thymosin Beta-4 fragment) to exploit complementary, non-redundant repair mechanisms. BPC-157 acts intracellularly, modulating growth hormone receptors, VEGF signalling, and fibroblast proliferation within damaged tissue. TB-500 acts extracellularly, binding to actin in the cytoskeleton and modulating cell migration, wound closure, and extracellular matrix remodelling. These two mechanisms address different phases of the tissue repair cascade — BPC-157 predominantly driving the vascular and receptor-signalling phase, TB-500 driving the cytoskeletal remodelling and cell migration phase. HPLC stability studies confirm that BPC-157 and TB-500 are co-stable when reconstituted together in BAC water, making them suitable for combination in a single custom pen at standard concentrations. The standard Wolverine Stack dose is 250 mcg BPC-157 + 750 mcg TB-500, once daily, delivered subcutaneously.
For researchers adding GHK-Cu (copper peptide) to the Wolverine Stack, this creates what is sometimes called the GLOW Stack — adding a third non-redundant mechanism: GHK-Cu's ability to upregulate anti-inflammatory and tissue-remodelling gene expression (notably TGF-β, collagen synthesis, and anti-oxidant enzyme upregulation). The GLOW Stack uses a 3 ml custom pen accommodating all three compounds within BAC water volume constraints.
Build Your Wolverine Stack Pen
Use the Pen Builder to create a custom BPC-157 + TB-500 pen. Pre-configured recipes with exact volumes and concentrations.
Biomarkers to Monitor
Serious researchers using BPC-157 protocols should establish a biomarker baseline before commencing and recheck at 8 weeks. The most relevant markers for BPC-157 research are: hs-CRP (high-sensitivity C-reactive protein) — the most sensitive marker of systemic inflammation, useful as a baseline and response indicator given BPC-157's documented anti-inflammatory mechanisms. Creatine Kinase (CK or CPK) — a direct marker of muscle and tendon tissue damage; elevated baseline CK indicates active tissue injury and provides context for repair research. ALT (Alanine Aminotransferase) — a liver enzyme worth monitoring given the hepatic processing of any compound. Albumin — reflects overall nutritional status and protein synthesis capacity, relevant to tissue repair research. These four markers provide a meaningful picture of inflammatory status, tissue integrity, and metabolic baseline for BPC-157 research protocols.
74-Biomarker Bloodwork Panel
Track hs-CRP, CK, ALT and 71 other longevity biomarkers with the Bioactive Compounds bloodwork tracker.
Myths & Misconceptions
Myth 1: "BPC-157 heals any injury quickly." The evidence does not support rapid, near-instantaneous healing. Animal studies show accelerated repair timelines measured in weeks, not days. The underlying biology of collagen remodelling and vascular remodelling operates on defined physiological timescales that no compound can compress dramatically. Myth 2: "It works the same as steroids." BPC-157 has a fundamentally different mechanism — it does not suppress the hypothalamic-pituitary axis, does not directly raise anabolic hormones, and does not have the immunosuppressive profile of corticosteroids. Myth 3: "More dose = more effect." Several animal studies show dose-response curves that plateau or exhibit bell-curve behaviour at high concentrations. Higher doses are not validated as more effective. Myth 4: "It's banned." BPC-157 is not listed under the Misuse of Drugs Act in the UK. It is a research chemical, not a controlled substance. However, WADA does list it on its monitoring programme.
Research Gaps — What We Don't Know Yet
Intellectual honesty demands acknowledging the significant gaps in the BPC-157 evidence base. The most critical: long-term human safety data is absent — there are no multi-year human studies examining carcinogenicity, immune effects, or organ-level changes. Optimal human dosing remains unknown — animal-to-human dose extrapolations using BSA conversion are estimates, not validated protocols. The systemic vs. local injection debate is unresolved — whether systemic subcutaneous injection produces equivalent tissue-level effects to local injection near injured tissue has not been systematically studied in humans. Most critically for certain populations: there is a theoretical concern about BPC-157 use in individuals with active malignancies, given its VEGF-activating and pro-angiogenic properties. While no evidence demonstrates tumour growth promotion, this theoretical risk means research protocols in oncology-adjacent populations require additional caution.
Legal Status in the UK
BPC-157 is a research chemical in the United Kingdom. It is not a licensed medicine under the Medicines Act, and is not approved for human therapeutic use by the MHRA (Medicines and Healthcare products Regulatory Agency). It is not a controlled substance under the Misuse of Drugs Act 1971 or the Psychoactive Substances Act 2016. Possession and purchase for legitimate research and educational purposes is lawful. WADA (World Anti-Doping Agency) includes BPC-157 in its monitoring programme. It does not appear on the EU's controlled substances list, though individual EU member states may have varying regulations for non-licensed research compounds.
Continue Your BPC-157 Research
Frequently Asked Questions
Yes. BPC-157 is uniquely stable in gastric acid — unlike most peptides, which are degraded by digestive enzymes. This was one of the original discoveries about the compound: it survives passage through the stomach with biological activity intact. Oral administration has shown efficacy in gut-related research models, and for gastrointestinal targets specifically, oral may be a pharmacologically rational route. However, systemic bioavailability via oral route is likely lower than subcutaneous injection for non-gastrointestinal targets such as tendons or muscles, as the compound must cross the intestinal epithelium to reach systemic circulation. For systemic research applications, subcutaneous injection remains the standard route.
Animal studies suggest measurable effects on tissue repair markers — such as collagen synthesis, vascular density, and tendon strength — within 1–2 weeks of consistent administration. Research protocols typically run 8–12 weeks for full endpoint assessment. Human timelines are less characterised, but most serious research protocols track biomarkers at 8-week checkpoints to assess response. It is important to note that tissue remodelling — regardless of which compound supports it — operates on fixed biological timescales. Collagen maturation and tendon remodelling cannot be compressed to days; they follow weeks-long physiological timescales.
BPC-157 has not been approved for human therapeutic use by any regulatory body, including the MHRA. Its safety profile in humans is extrapolated from preclinical animal studies, which have shown a broad safety window without significant organ toxicity in short-to-medium term rodent studies. Long-term human safety data — multi-year studies examining carcinogenicity, immune effects, and hormonal impacts — does not exist. There is also a theoretical concern regarding VEGF activation in individuals with active malignancies. All BPC-157 use in humans is research-only, and the absence of serious adverse events in anecdotal research populations should not be conflated with proven clinical safety. This compound is for research use only.
Yes — BPC-157 and TB-500 are one of the best-characterised peptide combinations in the research literature. They operate via complementary, non-redundant mechanisms: BPC-157 modulates intracellular growth hormone receptor signalling, VEGF pathways, and fibroblast activity; TB-500 (Thymosin Beta-4 fragment) acts extracellularly on actin in the cytoskeleton, driving cell migration and wound closure. HPLC stability studies have confirmed co-stability in BAC water at standard research concentrations, making combination in a single custom pen pharmacologically viable. The combination is known as the Wolverine Stack and is available as a pre-formulated custom pen.
Lyophilised (dry powder) BPC-157 in sealed vials is stable at room temperature for short periods during transport, but should be stored at 2–8°C for longer-term preservation. Once reconstituted with Bacteriostatic Water, the solution must be refrigerated at 2–8°C at all times and used within 28 days. Never freeze reconstituted solution — ice crystal formation can degrade peptide structure. Always swirl gently when mixing; never shake. Custom pens containing BPC-157 should be stored in the refrigerator between uses.
Research protocols most commonly use 250–500 mcg per dose, once daily, administered subcutaneously. For injury-focused local injection near a specific tissue, 200–250 mcg per site is standard. The research literature does not demonstrate that doses above 500 mcg produce proportionally greater effects; some studies show bell-curve dose responses at very high concentrations in animal models. Cycle lengths are typically 8–12 weeks on, 4–8 weeks off. There is no consensus on an "optimal" human dose as this has not been established in controlled human trials.
BPC-157 was originally discovered in human gastric juice protein, and gastrointestinal research is arguably its most extensively studied application. Animal models have shown beneficial effects in inflammatory bowel disease models, NSAID-induced gastric damage, intestinal fistula healing, short-bowel syndrome, and colitis models. The cytoprotective effects on gut epithelium and mucosal barrier integrity are among the most replicated findings in the BPC-157 literature. For gut-targeted research, oral administration is a rational route given the compound's acid stability, potentially delivering higher concentrations to gastrointestinal tissue than subcutaneous injection would.
BPC-157 is a research chemical in the UK. It is not a controlled substance under the Misuse of Drugs Act 1971, nor under the Psychoactive Substances Act 2016. It is not a licensed medicine under the Medicines Act. Possession and purchase for legitimate research and educational purposes is lawful in the UK. It is not approved for human therapeutic use by the MHRA. WADA includes BPC-157 on its monitoring programme — competitive athletes subject to anti-doping testing should note this. Always review the latest guidance from the relevant regulatory bodies, as research chemical classifications can change.